The Jackson Laboratory
The Jackson Laboratory is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at The Jackson Laboratory.
The Jackson Laboratory is a company.
Key people at The Jackson Laboratory.
Key people at The Jackson Laboratory.
The Jackson Laboratory (JAX) is an independent, non-profit biomedical research institution, not a for-profit company, focused on discovering the genetic basis for preventing, treating, and curing human diseases through mammalian genetics, genomics, and translational research.[1][2][6] Founded in 1929, it operates campuses in Bar Harbor, Maine; Farmington, Connecticut; Sacramento, California; Shanghai, China; and Yokohama, Japan, employing over 3,000 staff, including more than 200 Ph.D.s and M.D.s investigating cancers, heart disease, Alzheimer’s, diabetes, and other disorders.[1][2][7] JAX provides essential resources like genetically defined mouse models, preclinical services for drug developers, education programs, and bioinformatics tools such as the Mouse Genome Database, empowering the global biomedical community.[3][5][6]
As a NCI-designated Cancer Center and NIH Centers of Excellence holder, JAX bridges basic research with clinical applications, offering platforms for safety/efficacy testing in cancer, autoimmunity, neuromuscular, and rare diseases while distributing millions of mice annually to researchers worldwide.[1][3][5]
The Jackson Laboratory was founded in 1929 in Bar Harbor, Maine, by Clarence Cook Little, a former president of the University of Maine and University of Michigan, initially named the Roscoe B. Jackson Memorial Laboratory.[1][2][4] Little, driven by the need to uncover cancer's causes through mammalian research, built the campus on 13 acres donated by George Dorr, with initial funding from Roscoe B. Jackson (Hudson Motorcar Company head) and Edsel Ford.[1][2][4] This marked a pioneering shift, establishing cancer as a genetic disorder—a novel idea at the time.[1]
Early milestones included discovering a cancer-causing mouse mammary tumor virus, the first successful fertilized ova transfer, and Dr. Leroy Stevens' description of stem cells.[1][4] Post-WWII expansion brought NCI funding in 1938 and property donations; later developments included the 2000s Sacramento facility for model breeding/services, the 2012 Jackson Laboratory for Genomic Medicine in Connecticut, and the 2016 Maine Cancer Genomics Initiative.[4] During COVID-19, JAX provided testing, vaccine models, and intensified research.[4] Recent expansions include acquiring The New York Stem Cell Foundation to integrate mouse genetics, stem cells, and AI.[6]
JAX rides the wave of precision genomics and AI-driven drug discovery, translating mouse models with human data to tackle complex diseases amid rising demand for personalized medicine.[6][7] Its timing aligns with post-genomics era advances—90+ years of mammal research now intersects with CRISPR, single-cell sequencing, and AI, as seen in its stem cell/AI platform acquisition.[4][6] Market forces like biotech/pharma needs for reliable preclinical models (e.g., for oncology, rare diseases) favor JAX, which supplies irreplaceable resources amid regulatory pressures for better translation rates.[3][5][8]
JAX influences the ecosystem by standardizing genetic tools (e.g., Mouse Genome Database), enabling breakthroughs like stem cell discovery and bone marrow transplants, and fostering collaborations that shape cancer care (e.g., Maine Genomics Initiative).[1][4][5] It democratizes access for academics/biotechs, accelerating therapies while advancing computational biology in aging/addiction/Alzheimer’s.[1][7]
JAX is poised to lead in AI-augmented genomics, leveraging its new stem cell integration to bridge mouse-human gaps, predict disease via unique genomes, and fast-track therapies for cancer, neurodegeneration, and rare disorders.[6][7] Trends like multi-omics data explosion, AI modeling, and global preclinical demand will propel growth, potentially expanding AI platforms and international services.[4][6] Its non-profit model ensures sustained influence, evolving from mouse pioneer to pivotal translator in an era where genomic precision defines health outcomes—turning "possible" into "pivotal," as its mission states.[7]
